USPTO Examiner MI QIUWEN - Art Unit 1655

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19012840POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGSJanuary 2025June 2025Allow501YesNo
18948016PEONY STAMEN-DODDER COMPOSITE, AND ITS PREPARATION METHOD AND APPLICATIONNovember 2024January 2025Allow200YesNo
18926515GAME ATTRACTANT AND VARMINT REPELLENT COMPOSITIONS AND METHODSOctober 2024March 2025Allow511YesNo
18911447MEDICINAL MUSHROOM-BASED TOPICAL COMPOSITIONOctober 2024January 2025Allow411YesNo
18844892METHOD FOR IMPROVING HEALTH CONDITION OF MAMMAL OR FARM ANIMALSeptember 2024February 2025Allow500NoNo
18794793ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAMEAugust 2024January 2025Allow501YesNo
18764014FORMULATIONS AND METHODS FOR SKIN CAREJuly 2024December 2024Allow511YesNo
18757390STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSJune 2024December 2024Allow510NoNo
18750691STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSJune 2024March 2025Allow921NoNo
18736592TRADITIONAL CHINESE MEDICINE COMPOUND FOR PREVENTING AND TREATING AFRICAN SWINE FEVER, AND ITS EFFICIENCY ENHANCEMENT PROCESS AND APPLICATIONJune 2024October 2024Allow501NoNo
18736009PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDSJune 2024January 2025Allow821YesNo
18734602PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITIONJune 2024April 2025Allow1001YesNo
18669211Composition for Relieving Sleep Disorder and its Application Method ThereofMay 2024December 2024Allow700YesNo
18667139HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPYMay 2024January 2025Allow800YesNo
18661900COMPOSITION FOR TREATING BONE LOSSMay 2024July 2024Allow200NoNo
18659701COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOFMay 2024May 2025Allow1301YesNo
18655974STABILIZED COMPOSITIONS COMPRISING CANNABIDIOLMay 2024January 2025Allow901YesNo
18654377BARRIER GUARD TECHNOLOGYMay 2024December 2024Allow800YesNo
18639285METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACTApril 2024May 2025Allow1311YesNo
18635597METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACTApril 2024June 2025Allow1410NoNo
18621062TRADITIONAL CHINESE MEDICINE COMPOUND FOR IMPROVING TESTICULAR DYSFUNCTION, PREPARATION METHOD AND APPLICATION THEREOFMarch 2024October 2024Allow711YesNo
18436468FOODS TO PROMOTE BETTER HEALTH AND/OR TO MAINTAIN HOMEOSTAIS AND METHOD OF PRODUCTION THEREOFFebruary 2024December 2024Allow1011YesNo
18432512TIME RELEASE SLEEP AID SYSTEMFebruary 2024May 2025Allow1611YesNo
18429310SUSTAINABLE NANOCOMPOSITION FOR TREATMENT OF OSTEOPOROSISJanuary 2024June 2024Allow501NoNo
18410512PHYTOCHEMICAL/ NUTRACEUTICAL COMPOSITION FOR MULTIMODAL PROPHYLAXIS AGAINST AND TREATMENT OF VIRAL AND BACTERIAL INFECTION AND INFLAMMATIONJanuary 2024May 2025Allow1621YesNo
18407411METHOD OF PREVENTING CADMIUM-INDUCED LIVER TOXICITY USING A PLANT PRODUCT DERIVED FROM ACHILLEA MILLEFOLIUM L.January 2024August 2024Allow710NoNo
18391194METHOD OF TREATING ILLNESS USING LYOPHILIZED CAMEL URINEDecember 2023September 2024Allow911YesNo
18538812BOTANICAL FORMULATIONSDecember 2023December 2024Allow1201YesNo
18533558AQUEOUS WOUND HEALING FORMULATIONDecember 2023June 2025Abandon1811YesNo
18529504COMPOSITION FOR TREATING BONE LOSSDecember 2023April 2024Allow511YesNo
18515789CRYSTALLINE FORMS OF PSILACETINNovember 2023August 2024Allow901YesNo
18512157PEST CONTROL USING NATURAL PEST CONTROL AGENT BLENDSNovember 2023March 2024Allow410YesNo
18509499COMPOSITION FOR PREVENTING OR TREATING GASTRITIS OR PEPTIC ULCERNovember 2023March 2025Allow1610NoNo
18559889USE OF EXTRACELLULAR VESICLES OF RHIZOMA DRYNARIAE IN PREPARATION OF MEDICINE FOR TREATING ORTHOPEDIC DISEASESNovember 2023April 2025Allow1710NoNo
18505309Topical NSAID Formulation with Improved Skin AbsorptionNovember 2023February 2025Abandon1511NoNo
18388167METHOD OF TREATMENT OF CANCERSNovember 2023April 2024Allow610YesNo
18387298MEDICAL TREATMENT COMPOSITION, METHOD OF PREPARATION AND TREATMENT METHODNovember 2023June 2024Allow801YesNo
18493997STABILIZED COMPOSITIONS COMPRISING CANNABIDIOLOctober 2023April 2024Allow611YesNo
18381439PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDSOctober 2023April 2024Allow601YesNo
18381558BETA-ADRENERGIC AGONIST AND MUSCARINIC ANTAGONIST COMPOSITIONS AND METHODS OF USINGOctober 2023April 2024Allow611YesNo
18487399UVARIA GRANDIFLORA EXTRACT AS A BOTANICAL FUNGICIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFOctober 2023October 2024Abandon1211NoNo
18379955COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASEOctober 2023March 2025Allow1710NoNo
18476580STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONSSeptember 2023April 2024Allow711YesNo
18367577Preparation Method of Ginseng Composition with High Ginsenoside BioavailabilitySeptember 2023January 2024Allow411YesNo
18464967Composition for Relieving Sleep Disorder and its Application Method ThereofSeptember 2023April 2024Allow711YesNo
18241567CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONISTSeptember 2023April 2024Allow800YesNo
18239560OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONSAugust 2023November 2024Allow1510YesNo
18236081HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPYAugust 2023May 2024Allow800YesNo
18228222COMPOSITION FOR A FECAL-DERIVED STERILIZED POSTBIOTIC IN ANTI-AGING AND NEUROTHERAPEUTIC APPLICATIONSJuly 2023June 2024Allow1121YesNo
18226387PROMOTING GROWTH, YIELD, AND SALINITY TOLERANCE OF ACHILLEA FRAGRANTISSIMAJuly 2023November 2023Allow411NoNo
18357668USE OF ANTRODIA CINNAMOMEA FOR INCREASING ALCOHOL METABOLISM OR/AND HANGOVERJuly 2023August 2024Allow1310NoNo
18353992HORSERADISH AND CINNAMON MIXED EXTRACT COMPOSITION FOR SUPPRESSION OF AVIAN VIRAL EPIDEMIC DISEASESJuly 2023December 2023Allow510YesNo
18353172SAPONIN EXTRACTIONJuly 2023July 2024Allow1210YesNo
18353169SAPONIN EXTRACTIONJuly 2023October 2024Abandon1510NoNo
18222187ECM HYDROGEL FOR TREATING ESOPHAGEAL INFLAMMATIONJuly 2023January 2025Allow1810YesNo
18347535BLOOD PLASMA-CONTAINING COMPOSITIONSJuly 2023June 2025Abandon2310NoNo
18216965PROCESSES FOR PRODUCING LOW CHLOROPHYLL, HIGH POLAR LIPID COMPOSITIONS FROM ALGAL OILS AND EXTRACTSJune 2023June 2025Allow2311YesNo
18343765FREEZE-DRIED NIPA PALM POWDER AND METHOD OF MANUFACTURING THE SAMEJune 2023September 2023Allow311YesNo
18205792CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONISTJune 2023August 2023Allow310YesNo
18204345Method for preventing or treating diseases related to vascular endothelial cell activity regulation, comprising a step of administering Java pepper extractMay 2023June 2024Allow1210NoNo
18326924PLASMA COMPOSITIONS AND METHODS OF USE THEREOFMay 2023February 2025Abandon2001NoNo
18199613SKIN CARE FORMULATIONSMay 2023June 2024Allow1311YesNo
18199481TOPICAL CREAMSMay 2023December 2024Abandon1911NoNo
18198054COSMETIC COMPOSITIONMay 2023March 2024Allow1000YesNo
18197395TOPICAL COSMETIC COMPOSITIONSMay 2023July 2024Allow1400YesNo
18316759BRUISE REMOVAL CREAMMay 2023October 2023Allow501YesNo
18143528NATURAL MOISTURIZER PRODUCTSMay 2023May 2025Allow2411YesNo
18143151COMPOSITION AND METHOD OF TREATING FRAGILE SKINMay 2023August 2024Allow1510NoNo
18141692COSMETIC COMPOSITIONMay 2023June 2024Allow1311NoNo
18136078MAGNOLIA EXTRACT CONTAINING COMPOSITIONSApril 2023May 2024Allow1301YesNo
18136116SKIN CARE FORMULATIONSApril 2023May 2024Abandon1310NoNo
18299784METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACTApril 2023March 2024Allow1110YesNo
18299810METHODS OF TREATING ENDOMETRIOSIS AND OTHER NONCANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACTApril 2023April 2024Allow1211YesNo
18133410Vaporized Medicants and Methods of UseApril 2023February 2025Allow2220NoNo
18298929SUPPLEMENTATION OF BOVINE COLOSTRUM WITH OMEGA-3 FATTY ACIDSApril 2023October 2024Allow1910NoNo
18190938METHODS OF EXTRACTING MATERIALS FROM PLANT MATERIALMarch 2023April 2024Abandon1211NoNo
18123711BOTANICAL FORMULATIONSMarch 2023November 2023Allow800NoNo
18120689TOPICAL COMPOSITIONSMarch 2023November 2023Allow800YesNo
18119976PROCESS TO ENHANCE THE BIOACTIVITY OF ASHWAGANDHA EXTRACTSMarch 2023December 2024Allow2100YesNo
18044559INJECTION COMPOSITION CONTAINING ISOLATED MITOCHONDRIA, AND USE THEREOFMarch 2023June 2025Allow2700YesNo
18118686Agmatine Compositions for Treatment of OsteoarthritisMarch 2023October 2023Allow710NoNo
18114914CANNABIS-BASED PRODUCTS AND METHODSFebruary 2023July 2025Allow2810YesNo
18169522METHODS FOR EXTRACTING COMPOUND FROM GINSENG, GINSENG EXTRACT COMPRISING THE COMPOUND AND COMPOSITION FOR ENHANCING SKIN BARRIER COMPRISING THE SAMEFebruary 2023October 2023Allow811YesNo
18104511COSMETIC COMPOSITIONSFebruary 2023August 2023Allow700YesNo
18104030THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19January 2023October 2023Allow911YesNo
18094541PHYTOCHEMICAL/ NUTRACEUTICAL COMPOSITION FOR MULTIMODAL PROPHYLAXIS AGAINST AND TREATMENT OF VIRAL AND BACTERIAL INFECTION AND INFLAMMATIONJanuary 2023September 2023Allow911YesNo
18093126NATURAL CRYSTALLINE COLORANT AND PROCESS FOR PRODUCTIONJanuary 2023May 2023Allow400YesNo
18084009Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination ThereofDecember 2022March 2024Allow1411YesNo
18079638MARINE EXTRACT COMPOSITIONS AND METHODS OF USEDecember 2022September 2023Abandon1001NoNo
17989529OIL-BASED INSECTICIDAL AND INSECT REPELLENT COMPOSITIONSNovember 2022June 2023Allow720YesNo
18056716SYSTEM, METHOD, PROCESS AND NUTRIENT-RICH PRODUCT DERIVED FROM WINE DERIVATIVESNovember 2022September 2023Allow901NoNo
18051536TOPICAL CREAMSNovember 2022April 2023Allow1511YesNo
17975231PROCESSES FOR EXTRACTION OF OMEGA-3 CONTAINING BIOMASS OILS FROM DRIED BIOMASSOctober 2022November 2024Abandon2510NoNo
18050023METHODS OF TREATING ENDOMETRIOSIS AND OTHER NON-CANCER GYNECOLOGICAL DISORDERS WITH HEMP EXTRACTOctober 2022April 2023Allow511YesNo
18049961METHODS OF TREATING OVARIAN CANCER WITH HEMP EXTRACTOctober 2022April 2023Allow511YesNo
17774522COSMETIC COMPOSITION FOR PREVENTING SKIN AGING AND REDUCING SKIN WRINKLES, COMPRISING VIBURNUM STELLATO-TOMENTOSUM EXTRACTOctober 2022April 2025Allow3510NoNo
17968788CURCUMIN COMPOSITIONS AND METHODS OF USE AS AN NK3 ANTAGONISTOctober 2022May 2023Allow711YesNo
18046536PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND, COMPRISING INDIRUBIN DERIVATIVE AS ACTIVE INGREDIENTOctober 2022May 2023Allow700NoNo
17963350FEED ADDITIVE COMPOSITIONS AND METHODS OF USEOctober 2022March 2025Abandon2941NoNo
17961218NUTRITIONAL COMPOSITIONOctober 2022August 2023Allow1010NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MI, QIUWEN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
9
(69.2%)
Examiner Reversed
4
(30.8%)
Reversal Percentile
46.5%
Lower than average

What This Means

With a 30.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
104
Allowed After Appeal Filing
31
(29.8%)
Not Allowed After Appeal Filing
73
(70.2%)
Filing Benefit Percentile
42.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 29.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MI, QIUWEN - Prosecution Strategy Guide

Executive Summary

Examiner MI, QIUWEN works in Art Unit 1655 and has examined 1,913 patent applications in our dataset. With an allowance rate of 67.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.

Allowance Patterns

Examiner MI, QIUWEN's allowance rate of 67.8% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MI, QIUWEN receive 1.62 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MI, QIUWEN is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +51.8% benefit to allowance rate for applications examined by MI, QIUWEN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.5% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.0% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 52.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 44% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.4% of appeals filed. This is in the 72% percentile among all examiners. Of these withdrawals, 55.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 46.9% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.9% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.